Well Referenced

Tag: patient-reported outcomes

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

This 2020 prospective cohort study evaluated five-year patient-reported outcomes in 2,005 men with localized prostate cancer treated with active surveillance, prostatectomy, brachytherapy, or external beam radiation therapy (EBRT), with or without androgen deprivation therapy (ADT). Results showed that prostatectomy led to greater declines in urinary continence and sexual function, particularly

Read More »
June 26, 2025 No Comments

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

This large-scale longitudinal study assessed the functional and quality of life outcomes in 2,565 men aged 50–69 with localized prostate cancer, randomized to active monitoring (AM), radical prostatectomy (RP), external-beam radiotherapy (EBRT) with androgen deprivation therapy (ADT), or low-dose-rate brachytherapy (BT). Over six years, AM was associated with gradual declines

Read More »
June 26, 2025 No Comments

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

This 2023 observational study (Radiation Oncology, PMID: 36879290) evaluated 112 lung cancer patients, primarily with non-small-cell lung cancer (median age 70), to assess the impact of adjunctive Viscum album L. (mistletoe) therapy on quality of life (QoL) during standard treatments, including radiation. Over 12 months, patients receiving radiation plus VA

Read More »
June 26, 2025 No Comments

Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients

This 2020 observational study (Integrative Cancer Therapies, PMID: 32478590) evaluated the impact of add-on Viscum album L. (mistletoe) therapy on cancer-related fatigue, internal coherence, and quality of life in 319 nonmetastasized breast cancer patients over 24 months. While chemotherapy, immunotherapy, and endocrine therapies were associated with worsened fatigue (by 17,

Read More »
June 26, 2025 No Comments

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document

The article titled “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document” examines the inconsistent benefits of levothyroxine (LT4) and liothyronine (LT3) combination therapy for hypothyroidism, despite its widespread use due to patient-reported benefits. A joint conference by the American, British, and European Thyroid Associations reviewed clinical evidence

Read More »
June 26, 2025 No Comments

A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism

This systematic review evaluates the safety of combining levothyroxine (LT4) and triiodothyronine (T3) for hypothyroidism treatment, particularly assessing the risk of thyrotoxicosis. Despite mixed evidence on clinical benefits, some patients report symptom improvement with LT4+T3 therapy. The review finds that safety concerns, especially regarding thyrotoxicosis, are minimal when LT4:T3 ratios

Read More »
June 26, 2025 No Comments

Blue-Light Therapy for Acne Vulgaris: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis evaluated the effectiveness of blue-light therapy in treating acne vulgaris, analyzing 14 randomized controlled trials with a total of 698 participants. The study found that while some trials reported significant investigator-assessed and patient-reported improvements, the mean differences in inflammatory and non-inflammatory lesion counts were not

Read More »
June 26, 2025 No Comments